EpimedX LLC is a biotechnology company developing Gene Regulation Therapy for sickle cell disease, beta-thalassemia, and malaria. The company's technology provides a safe, cost-effective, and permanent treatment that was previously unavailable for these diseases. The EDX-17 therapeutic under development would reverse sickle cell disease and a related disorder called beta-thalassemia, by restoring fetal hemoglobin in adult humans who carry the sickle cell gene. The company was awarded a Bill and Melinda Gates Foundation Grant in 2011 to pursue the application of their therapeutic for Maleria and will help the company develop a human clinical trial and advance a possible cure for the millions worldwide suffering from sickle cell and malaria.
